MIRUM PHARMACEUTICALS INC (MIRM)
Health Care · biotechnology · NASDAQ
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative, minimally-absorbed therapies for rare cholestatic liver diseases.
What MIRUM PHARMACEUTICALS INC does
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for rare liver diseases. The company markets three approved products: Livmarli, an ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in patients with Alagille syndrome and PFIC; and bile acid medicines Cholbam and Ctexli for bile acid synthesis disorders and cerebrotendinous xanthomatosis. Its pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, and additional early-stage programs.
Themes: rare disease therapies, cholestatic liver disease, IBAT inhibitors, gastroenterology / hepatology
Fundamentals
- Price$96.72 as of 2026-08-24 close
- Market cap$6.3B as of 2026-08-24
- 1-year return+35.2% 2025-08-22 close $71.52 → 2026-08-24 close $96.72
- P/En/a negative earnings
- Net margin-139.2% as of 2026-08-24
- Gross margin+81.7% as of 2026-08-24
- ROE-289.3% as of 2026-08-24
- Debt / equity1.28 as of 2026-08-24
- Revenue growth (YoY)+44.0% as of 2026-08-24
- Revenue CAGR (3y)+89.1% SEC XBRL
- Beta0.83 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How MIRM compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MIRM is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no valuation data.
Short-term score
39.6 #1417 of 1,704 scored · #212 of 240 in Health Care
Catalysts 52nd: open-market insider buys in 90 days 25, the analyst consensus rating is unchanged since the prior reading; setup 47th: over the past year its closes ranged, and it has retraced around half of its move over the past year — 50% of it; weakest is trend 29th: a strong downtrend, with sellers in control.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How MIRUM PHARMACEUTICALS INC looks technically
MIRUM PHARMACEUTICALS INC (MIRM) is trading 2.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 291 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day low about 12 trading days ago. It is 25.9% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 2.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +2.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $110.53 | $110.53 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $94.03 | $94.03 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 291 trading days ago — a "golden cross", a bullish long-term signal | 291 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control | 34.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30) | 37.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($88.88 to $107.00) — its "stochastic" reading is 41 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 41.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $130.00 | $130.00 |
|---|---|---|
| From the 52-week high | it is 25.9% below its 52-week high (its highest price of the past year) | -25.9% |
| Above the 52-week low | it is 52.3% above its 52-week low (its lowest price of the past year) | +52.3% |
| Below the 52-week high | it is 25.9% below its highest point of the past year | 25.9% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $130.00 (set on 2026-07-09) | $130.00 |
| Given back of the 52-week move | over the past year its closes ranged ($64.10 to $128.57), and it has given back around half of its rise from last year’s low — 50% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $86.66 to $88.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 50.0% |
| From the all-time high | it is 25.9% below its all-time high | -25.9% |
| Nearest price level | it is trading 0.8% below a resistance level at $97.07 — a price it turned at twice since 2026-02-06, most recently on 2026-03-17. Since 2024-08-21 it has 15 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.8% |
| All-time low | its lowest closing price on record is $6.51 (set on 2019-11-20) | $6.51 |
| Above the all-time low | it is 1378.8% above its all-time low | +1,379% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.50 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.50 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $91.70 and $113.66 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $91.70 – $102.68 – $113.66 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 0.5 daily ranges above its 200-day average price (2.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.09× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.0% since the prior reading | -0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Open gap | it gapped 14.7% below the previous close 11 sessions ago and has not traded back through the level it left behind at 105.79 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -14.7% |
| Gap filled | a 2.1% gap down opened on 2026-06-23 has been "filled" 42 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 42 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.8% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 20.0 percentage points (the stock lost 17.7% while the market gained 2.3%) | -20.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 7.4 percentage points (the stock lost 4.3% while the market gained 3.1%) | -7.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.5 percentage points (the stock lost 8.4% while the market gained 11.1%) | -19.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 19.0 percentage points (the stock gained 39.5% while the market gained 20.5%) | +19.0% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 8.0% of the share price. | -11.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $100.83 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -4.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $98.37 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -2.1% |
Price levels it has turned at before
MIRM last closed at $96.31 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $97.07 | Resistance | 0.8% above the last close | turned there twice · 2026-02-06 to 2026-03-17 |
| $90.30 | Support | 6.3% below the last close | turned there twice · 2026-04-24 to 2026-06-03 |
| $88.61 | Support | 8.0% below the last close | turned there twice · 2026-05-04 to 2026-08-06 |
| $84.64 | Support | 12.1% below the last close | turned there twice · 2026-03-09 to 2026-03-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · lagging the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$138.21 range $118.00 – $183.00; median $137.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MIRM
- Consensus EPS estimate-$0.425 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on successful commercialization of currently approved and future therapies.","Risks associated with clinical trial outcomes and regulatory approval timelines for pipeline candidates.","History of operating losses and the need for additional capital to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of MIRM's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) references Annual Report for year ended December 31, 2025, filed February 25, 2026
- Newer filing adds that Livmarli approved for cholestatic pruritus in PFIC in Canada and Japan
- Newer filing adds volixibat Breakthrough Therapy designation specifically 'as a potential treatment for cholestatic pruritus in patients with PBC' (October 2024)
- Newer filing reports VISTAS Phase 2b topline results announced May 2026
- Newer filing states NDA submission expected second half of 2026 for volixibat in PSC
- Newer filing states approval and launch expected first half of 2027 for volixibat in PSC
- Newer filing reports VANTAGE Phase 2b enrollment expected to complete second half of 2026 with topline data first quarter of 2027
- Newer filing states EXPAND study completed enrollment in first half of 2026 with topline data expected fourth quarter of 2026
- Newer filing adds acquisition of Bluejay Therapeutics completed January 23, 2026, including brelovitug (BJT-778)
- Newer filing adds brelovitug details: fully human IgG1 monoclonal antibody for chronic hepatitis D virus, FDA Breakthrough Therapy and EMA PRIME designations
- Newer filing adds AZURE clinical program with AZURE-1 and AZURE-4 topline results expected second half of 2026
- Newer filing adds AZURE-2 and AZURE-3 topline results expected first half of 2028
- Newer filing adds BLA submission expected first half of 2027 for brelovitug
- Newer filing adds potential approval and launch second half of 2027 for brelovitug in U.S.
- Newer filing adds April 2026 agreement with Incyte for zilurgisertib commercialization rights
- Newer filing adds zilurgisertib is oral small molecule ALK2 inhibitor for fibrodysplasia ossificans progressiva
- Newer filing adds FDA accepted Incyte NDA with PDUFA date September 26, 2026 for zilurgisertib
- Removed:
- Older filing (2025-11-04) references Annual Report for year ended December 31, 2024, filed February 26, 2025
- Older filing lists product as 'CHENODAL® or CTEXLI®' (removed 'CHENODAL' reference in newer)
- Older filing states Livmarli approved for PFIC in U.S. only (no Canada or Japan mentioned)
- Older filing describes chenodiol as 'standard of care' and previously commercialized as 'Chenodal'
- Older filing includes detailed history of Travere Therapeutics asset acquisition (August 31, 2023)
- Older filing states EXPAND study expected to complete enrollment in 2026 with topline in first half of 2027
- Older filing states VISTAS completed enrollment third quarter 2025 with topline expected second quarter 2026
- Older filing states VANTAGE expected to complete enrollment in 2026 with topline in first half of 2027
- Older filing states Phase 2 multi-dose safety and efficacy trial for MRM-3379 'has begun enrolling patients'
- Older filing includes 'Financial Overview' section with specific financial metrics for periods ended September 30, 2025 and 2024
- Reworded:
- Older: 'received approval from the Japanese Ministry' changed to newer: 'received approval from the Japanese Ministry of Health, Labour, and Welfare' (addition of full ministry name)
- Older: 'A Phase 2 multi-dose safety and efficacy trial has begun enrolling patients' changed to newer: 'We are currently enrolling patients in the BLOOM Phase 2 clinical study' (addition of study name BLOOM)
- Older: License agreement date stated as 'October 22, 2024' changed to newer: 'October 2024' (less specific)
- Older: 'We intend to develop MRM-3379 for the treatment of Fragile-X Syndrome' changed to newer: 'for the treatment of Fragile-X Syndrome' with addition of 'and expect topline data in 2027'
- Older: Refers to 'VISTAS Phase 2b clinical trial' enrollment completion timing; newer specifies 'topline results announced May 2026'
- Older: Includes Travere asset purchase agreement details; newer: omits this historical information entirely
- Notes:
- The older filing text appears truncated at the end ('We anticipate we wi'), preventing full comparison of the Financial Overview section and any content that follows
- Dates for MRM-3379 development shifted from general '2026' completion in older filing to more specific 'topline data in 2027' in newer filing
- Older filing provides specific financial metrics (net income, accumulated deficit, cash) for September 30, 2025; these sections are not present in the provided excerpt of the newer filing
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 25 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 5 sells ($3M) — 3 selling insiders
- Last 90 days0 buys · 25 sells ($10M) — 4 selling insiders
- Last 180 days0 buys · 27 sells ($11M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MIRM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MIRM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,401,819
- Reported value $868,540,062
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MIRM had 6,823,706 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MIRM had 10.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.05 days to cover at the same settlement.
- Reported short interest (shares) 6,823,706
- Short interest (% of shares outstanding) 10.5%
- Prior settlement (shares) 7,272,892
- Reported change -6.18%
- Days to cover (reported) 12.05
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Albireo (acquired by Ipsen)
- Ipsen (IPSEY)
- Intercept Pharmaceuticals (acquired by Alfasigma)
- Travere Therapeutics (TVTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MIRM vs…
Frequently asked questions
What does MIRUM PHARMACEUTICALS INC (MIRM) do?
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for rare liver diseases. The company markets three approved products: Livmarli, an ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in patients with Alagille syndrome and PFIC; and bile acid medicines Cholbam and Ctexli for bile acid synthesis disorders and cerebrotendinous xanthomatosis.
What sector is MIRUM PHARMACEUTICALS INC (MIRM) in?
MIRUM PHARMACEUTICALS INC (MIRM) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are MIRUM PHARMACEUTICALS INC's (MIRM) competitors?
Notable peers of MIRUM PHARMACEUTICALS INC (MIRM) include Albireo (acquired by Ipsen), Ipsen, Intercept Pharmaceuticals (acquired by Alfasigma) and Travere Therapeutics. This peer set is informational only — not financial advice.
Is MIRUM PHARMACEUTICALS INC (MIRM) overbought or oversold right now?
MIRUM PHARMACEUTICALS INC (MIRM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MIRM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.